Your session is about to expire
← Back to Search
MORF-057 for Ulcerative Colitis
Study Summary
This trial will test if a new medication is effective and safe for people with moderate to severe ulcerative colitis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am able to understand and sign the consent form.I cannot attend the study visits or follow the study procedures.I have had moderate to severe ulcerative colitis symptoms for at least 3 months.I have not tried or did not respond well to other ulcerative colitis drugs.I have a serious health condition besides my cancer.My condition did not improve with vedolizumab or similar medications.I have had an allergic reaction to MORF-057 or similar drugs.I have been diagnosed with a specific type of colitis or have symptoms that may suggest Crohn's disease.My ulcerative colitis extends 15 cm from the anal verge.
- Group 1: MORF-057
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many venues are offering this research program?
"This clinical trial is currently enrolling patients from 11 different medical centres, including Houston, Boston and Southlake. To reduce travel requirements, it is recommended that you select the closest site to your area if you decide to participate in this study."
Are there still opportunities to participate in this clinical examination?
"Indeed, clinicaltrials.gov affirms that this research endeavour is accepting participants at the moment. It was initially posted on May 24th 2022 and its information has been amended as recently as November 1st of the same year. 35 patients are expected to be recruited from 11 different centres across the country."
What potential dangers should be taken into consideration when administering MORF-057?
"MORF-057 is believed to be moderately safe, as evidenced by the rating of 2. This pharmaceutical has been tested in Phase 2 trials resulting in some safety data but no information on efficacy yet."
What is the minimum age requirement for enrollment in this research program?
"The requirements for this experiment stipulate that the minimum age of participation is eighteen and no older than eighty-five."
Am I eligible to partake in this particular experiment?
"This research is seeking 35 individuals aged between 18 and 85 years with a diagnosis of ulcerative colitis. To be accepted, they must have evidence of UC extending at least 15 cm from the anal verge, moderate to severe symptoms for at least 3 months prior to screening, no or limited response to other medications related to their condition, willingness to abide by study conditions, and ability to provide informed consent."
What is the total enrollment for this medical research trial?
"Affirmative. Clinicaltrials.gov exhibits that this research is currently enrolling eligible participants, having initially been published on May 24th 2022 and most recently updated 11/1/2022. 35 volunteers are sought from 11 distinct sites."
Share this study with friends
Copy Link
Messenger